| 產(chǎn)品詳情 |
| Edit |   |
|---|
| Product Name | CCG-1423 |
|---|
| Description | CCG-1423 is a specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription. CCG-1423 displays activity in several in vitro cancer cell functional assays. CCG-1423 potently (<1 mumol/L) inhibits lysophosphatidic acid-induced DNA synthesis in PC-3 prostate cancer cells, and whereas it inhibits the growth of RhoC-overexpressing melanoma lines at nanomolar concentrations, it is less active on related lines that express lower levels of Rho. Similarly, CCG-1423 selectively stimulates apoptosis of the metastasis-prone, RhoC-overexpressing melanoma cell line (A375M2) compared with the parental cell line (A375). MW: 454.75. Purity ≥98% by HPLC |
|---|
| Size | 5 mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | N-[2-[(4-Chlorophenyl)amino]-1-methyl-2-oxoethoxy]-3,5-bis(trifluoromethyl)benzamide |
|---|
| Gene, Accession, CAS # | CAS: 285986-88-1 |
|---|
| Catalog # | 9434-5 |
|---|
| Price | |
|---|
| Order / More Info | CCG-1423 from BIOVISION, INC. |
|---|
| Product Specific References | n/a |
|---|
| 產(chǎn)品資料 |
|
|